- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01060150
An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)
August 14, 2013 updated by: Janssen Korea, Ltd., Korea
Efficacy and Learning Skill After OROS Methylphenidate Treatment in Adolescents With Attention-Deficit/Hyperactivity Disorder: A 12-week, Multi-center, Open-label Study
The purpose of this study is to evaluate the efficacy, tolerability and effects of Osmotic Release Oral System (OROS) methylphenidate hydrochloride (HCl) on learning skill changes in Korean participants with Attention-Deficit Hyperactivity Disorder (ADHD).
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This is 12 week, open label (all people involved know the identity of the intervention), prospective (study following participants forward in time), single arm, multicenter study (when more than one hospital or medical school team work on a medical research study) of OROS methylphenidate HCl.
The study will consist of 6 visits at Screening, Baseline, Week 1, 3, 6 and 12.
The participants already on other ADHD medications in addition to methylphenidate will be required to undergo a washout period (period when receiving no treatment) of at least 1 week.
The participants will be on once daily study medication starting at 18 milligram per day (mg/day) in participants with less than 30 kilogram (kg) of body weight or at 27 mg/day in participants with more than 30 kg.
The dose will be increased by 9 mg or 18 mg every week for up to Week 6 based on the treatment efficacy and tolerability, followed by a maximum maintenance dose of 72 mg orally once daily up to Week 12, during which the dose can be decreased by 9 mg depending on tolerability.
Efficacy will primarily be assessed using Clinical Global Impression of Severity of Illness (CGI-S) scale, Clinical Global Impression of Improvement of Illness (CGI-I) scale, Korean version of ADHD-IV Rating Scale (K-ARS) and Learning Skill Test (LST) score.
Participants' safety will be monitored.
Study Type
Interventional
Enrollment (Actual)
115
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants must meet Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for Attention Deficit Hyperactivity Disorder (ADHD) and are considered to require medication therapy
- Participants that agreed to observe visit schedules and willingly complete the evaluation defined by participant (possibly to be completed by parents/guardians) during the treatment period
- Participants and parents/guardians that are able to understand the participation procedures of the research and spontaneously request the discontinuation therein at any time
- Participants that offered spontaneous consent for participation
- Participants whose guardian/legal representative provided spontaneous written consent
Exclusion Criteria:
- Hypersensitivity to methylphenidate HCl
- Participants diagnosed with major depression or anxiety disorders according to DSM-IV Diagnostic criteria and who requires drug therapy
- Participants with a history of bipolar disorder, psychotic disorder, and substance abuse disorder ordiagnosed with an overall developmental disorder, organic brain disorder, seizure (sudden, uncontrolled muscle spasms and loss of consciousness resulting from abnormal brain function) disorder, movement disorder requiring the medication therapy, or with a family history of Tourette's syndrome (a neuropsychological disorder that causes marked distress or significant impairment in social, occupational, or other important areas of functioning)
- Taken Osmotic Release Oral System (OROS) Methylphenidate within 3 months prior to screening
- Currently taking alpha-2 adrenergic receptor agonist, antidepressant, antipsychotic, benzodiazepines, modafinil, anticonvulsant (drug used to stop seizures) or health food supplements that may have a central nervous system activity
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OROS Methylphenidate HCl
|
Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of body weight and 27 mg for those more than or equal to 30 kg; the dose can be increased by 9 mg or 18 mg per week up to Week 6 depending on a participant's treatment effect and tolerability; then a maximum maintenance dose of 72 mg will be given orally once daily up to Week 12.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Korean Version of the Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (K-ARS) Score
Time Frame: Week 12
|
The K-ARS is a rating scale that is used for the ADHD diagnosis and the assessment of treatment efficacy and comprises 18 items in total on the basis of Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), each item being rated from 0-3 points.
The total score ranges from 0-54 with 0=normal and 54=severe condition.
|
Week 12
|
Clinical Global Impression - Severity (CGI-S) Score
Time Frame: Week 12
|
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.
A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants".
Higher scores indicate worsening.
|
Week 12
|
Clinical Global Impression - Improvement (CGI-I) Score
Time Frame: Week 12
|
The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
|
Week 12
|
Learning Skill Test (LST) Total Score
Time Frame: Week 12
|
The LST measures learning ability of student.
This scale is composed of 7 sections: self control, participation, task accomplishment, reading, writing, test taking and information processing.
It consists of 70 items for middle school student (age 13-15 years) and 80 items for high school student (age 16-18 years).
Each item is rated on a 5-point Likert scale ranging from 1 (never) to 5 (always).
The total score range is 70-350 for middle school version and 80-400 for high school version where higher score indicates better ability for learning.
In result analysis, each sub-score and total score was converted to T-score for normalization.
The score range of T-score is from 1 to 100 with a mean of 50.
Higher score indicates better ability for learning.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Attention-Deficit/Hyperactivity Disorder (ADHD) Diagnostic System (ADS) Test Result for Omission Errors and Commission Errors
Time Frame: Baseline and Week 12
|
The ADS is composed of 4 factors: omission/missing frequency to measure attention dispersibility; false alarm/commission frequency to measure impulse; mean response/reaction time to measure the speed of task processing; and the response variability/standard deviation of response time to measure the consistency of attention.
The total value for both, omission errors and commission errors, ranges from 0-100 errors where high value indicates worsening attention.
|
Baseline and Week 12
|
Attention-Deficit/Hyperactivity Disorder (ADHD) Diagnostic System (ADS) Test Score for Reaction Time and Response Variability
Time Frame: Baseline and Week 12
|
The ADS is composed of 4 factors: omission/missing frequency to measure attention dispersibility; false alarm/comission frequency to measure impulse; mean response/reaction time to measure the speed of task processing; and the response variability/standard deviation of response time to measure the consistency of attention.
The score range for both, reaction time and response variability, is 0-100.
High score indicates worsening attention.
If one or over factor's score is over 65 point, the participant is resulted in having attention deficit.
|
Baseline and Week 12
|
Digit Span Test Score
Time Frame: Baseline and Week 12
|
Each participant individually was given a sequence of numbers, with the sequence becoming progressively longer, to repeat the digits in the same sequence, either forwards or backwards.
Each sequence length was attempted twice.
The test was complete after failure on both trials of any sequence length. 1 point was awarded if the participant passed only 1 trial of a sequence length.
0 points were given if the participant failed both trials.
Total score range was 0-16 (forwards) and 0-14 (backwards).
A higher score was indicative of better recall and attention.
|
Baseline and Week 12
|
Finger Window (FW) Test Score
Time Frame: Baseline and Week 12
|
In FW test, a participant shows memory of a demonstrated visual pattern using a 8x11 inch plastic template containing 9 asymmetrically located holes.
The examiner models a given sequence of holes and asks the participant to imitate the sequence by placing his/her finger through the same holes in the correct order.
The total number of correct sequences constitutes the total score which ranges from 0-24 (forward FW) and 0-28 (backward FW) with higher score indicating a more favorable health state.
|
Baseline and Week 12
|
Controlled Oral Words Association Test (COWAT) Score
Time Frame: Baseline and Week 12
|
This test measures the executive function of the frontal lobe and is consisted of examinations of category/meaning fluency and letter/phoneme fluency.
It consisted of three 60 second word generation trials in which the participant orally generates as many words as possible that begin with target letters F, A and S. Dependent variables included total number of acceptable words generated for each target letter and total number of words generated across all three letter trials.
Total score was calculated as sum of acceptable words generated, with higher scores indicating better verbal fluency.
|
Baseline and Week 12
|
Stroop Test Result for Reaction Time
Time Frame: Baseline and Week 12
|
This test consists of 3 trials: color trial (simple execution), word trial (middle execution) and word-color interference trial (interfering execution).
In simple execution, participants have to read the written color names of the words independent of the color of the ink.
In middle execution, participants have to read words written in black letters.
In interfering experiment, participants have to say the color of the letters independent of the written word.
This test estimates spending time for execution.
High spending time indicates low ability of suppression of automation.
|
Baseline and Week 12
|
Stroop Test Result for False Reaction
Time Frame: Baseline and Week 12
|
This test consists of 3 trials: color trial (simple execution), word trial (middle execution) and word-color interference trial (interfering execution).
In simple execution, participants have to read the written color names of the words independent of the color of the ink.
In middle execution, participants have to read words written in black letters.
In interfering experiment, participants have to say the color of the letters independent of the written word.
The total value ranges from 0-24 errors for each execution where high value indicates worsening attention.
|
Baseline and Week 12
|
Stroop Test Score for Ratio Interference
Time Frame: Baseline and Week 12
|
Ratio interference is calculated by dividing simple execution time by interfering execution time.
The score range is 0-1.
Higher value indicates better ability of suppression of automation.
|
Baseline and Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2008
Primary Completion (Actual)
April 1, 2010
Study Completion (Actual)
April 1, 2010
Study Registration Dates
First Submitted
January 21, 2010
First Submitted That Met QC Criteria
January 29, 2010
First Posted (Estimate)
February 2, 2010
Study Record Updates
Last Update Posted (Estimate)
August 23, 2013
Last Update Submitted That Met QC Criteria
August 14, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Disease
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Methylphenidate
Other Study ID Numbers
- CR015496
- CON-KOR-4019
- CONCERTAATT4082
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Disorder With Hyperactivity
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Karolinska InstitutetCompletedAttention Deficit Disorder With Hyperactivity (ADHD)Sweden
-
Rabin Medical CenterNG Solutions LtdRecruitingADHD - Attention Deficit Disorder With HyperactivityIsrael
-
Fondation LenvalCompletedAttention Deficit Disorder With Hyperactivity | Attention Deficit Disorder Without HyperactivityFrance
-
Clinical and Translational Genome Research Institute...Children's Specialized HospitalTerminatedAttention Deficit Disorders With HyperactivityUnited States
-
University of PennsylvaniaCompletedAttention Deficit Disorder With Hyperactivity (ADHD)United States
-
Nemours Children's ClinicCompletedAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit DisorderUnited States
-
Massachusetts General HospitalRecruitingAttention Deficit Disorder With Hyperactivity | Attention Deficit DisorderUnited States
-
New River PharmaceuticalsShireCompletedAttention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersUnited States
Clinical Trials on OROS Methylphenidate HCl
-
Massachusetts General HospitalMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Completed
-
Alza Corporation, DE, USACompleted
-
University of CincinnatiNational Institute on Drug Abuse (NIDA); University of Colorado, DenverCompletedADHD | Substance AbuseUnited States
-
Alza Corporation, DE, USACompleted
-
Alza Corporation, DE, USACompleted
-
Massachusetts General HospitalOrtho-McNeil Janssen Scientific Affairs, LLCCompleted
-
Janssen-Cilag International NVCompletedAttention Deficit Disorder With HyperactivityFrance, Germany, Spain, Switzerland, Netherlands, Portugal, Norway
-
Janssen-Cilag International NVCompletedAttention Deficit/ Hyperactivity DisorderFrance, Belgium, Germany, Spain, Switzerland, Denmark, Finland, Netherlands, Norway, Sweden, United Kingdom
-
Massachusetts General HospitalFood and Drug Administration (FDA); Center for Psychiatry And Behavioral Medicine...Completed
-
Children's Hospital Medical Center, CincinnatiNational Institute of Mental Health (NIMH)CompletedADHD - Combined Type | ADHD - Inattentive TypeUnited States